Noninvasive cancer treatment

搜索文档
Novocure: Steady Ahead of Key Milestones
The Motley Fool· 2025-07-24 21:21
Here's our initial take on Novocure's (NVCR -12.17%) fiscal 2025 second-quarter financial report.Key MetricsMetricQ2 2024Q2 2025Changevs. ExpectationsRevenue$150.4 million$158.8 million6%BeatEarnings per share-$0.31-$0.36N/ABeatGross margin77%74%-300 bpn/aTotal active patients3,9634,3319%n/aSlow and Steady Progress for NovocureNovocure reported no surprises in its latest quarter, with revenue up 6% for the year and both revenue and loss per share topping Wall Street expectations. The company, which is devel ...